Mehmet Asim Bilen, MD

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.

Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.

Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.

Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.

David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.

Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.

Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.

Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.